Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Antonio TursiGiammarco MocciLeonardo AllegrettaGiovanni AragonaMaria Antonia BiancoRaffaele ColucciAntonio CuomoNicola Della ValleAntonio FerronatoGiacomo FortiFederica GaianiMaria Giovanna GrazianiRoberto LorenzettiFrancesco LuzzaPietro PaeseAntonio PennaRoberta PicaGiuseppe PranzoStefano RodinòAntonella ScarcelliCostantino ZampalettaLorenzo BrozziClelia CiceroneAndrea CoccoGianluigi De' AngelisLaura DonnarummaSerafina FiorellaChiara IannelliTiziana LarussaMarco Le GrazieIleana LuppinoCostantino MeucciRoberto FaggianICristiano PagniniPatrizia PerazzoKryssia Isabel Rodriguez-CastroRodolfo SaccoLadislava SebkovaMariaelena SerioAlberta De MontiMarcello PicchioDaniele NapolitanoElisa SchiavoniLaura TurchiniFranco ScaldaferriDaniela PuglieseLuisa GuidiLucrezia LaterzaGiuseppe PriviteraMarco PizzoferratoLoris Riccardo LopetusoAlessandro ArmuzziWalter EliseiGiovanni MaconiAlfredo PapaPublished in: Expert opinion on biological therapy (2021)
This first comparative study found that both IFX biosimilars CT-P13 and SB2 are effective and safe in managing IBD outpatients.